Veradermics (MANE) Non Operating Income (2025 - 2026)

Veradermics posted quarterly Non Operating Income of $2.6 million for Q1 2026, up 410.68% year-on-year from $515000.0 in Q1 2025, and up 410.68% on a QoQ basis from $515000.0 in Q1 2025.

Veradermics (MANE) has 2 years of Non Operating Income data on file, last reported at $2.6 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 444,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 201.20 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -46.98 Mn
10 Veradermics 2.29 Bn 2.29 Bn - 2.63 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 2.63 Mn
Mar 31, 2025 515,000.00